Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20110445 | 0.83 | MEN1 (0.45) | NPSR1MEN1KMT2APKMHTT | |
| SCHEMBL20110437 | 0.83 | MEN1 (0.45) | NPSR1MEN1KMT2APKMHTT | |
| SCHEMBL13921741 | 0.79 | MEN1 (0.47) | NPSR1MEN1KMT2APKMHTT | |
| SCHEMBL30087363 | 0.78 | L3MBTL1 (0.43) | NPSR1MEN1KMT2APKMHTT | |
| SCHEMBL18831779 | 0.75 | ANPEP (0.40) | NPSR1MEN1KMT2APKMHTT | |
| SCHEMBL25387275 | 0.75 | BTN3A1 (0.53) | NPSR1MEN1KMT2ASRCL3MBTL1 | |
| SCHEMBL12870471 | 0.75 | BTN3A1 (0.53) | NPSR1MEN1KMT2ASRCL3MBTL1 | |
| SCHEMBL23992574 | 0.75 | BTN3A1 (0.53) | NPSR1MEN1KMT2ASRCL3MBTL1 | |
| SCHEMBL800889 | 0.75 | BTN3A1 (0.53) | NPSR1MEN1KMT2ASRCL3MBTL1 | |
| SCHEMBL23044635 | 0.74 | MEN1 (0.43) | NPSR1MEN1KMT2APKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012078416-A2 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | RFS PHARMA, LLC (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | NPSR1 2162/4885MEN1 2253/4885KMT2A 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.